The SBRT + αPD-1 + CCR2/5i treatment group demonstrated significantly better local tumor control, better metastasis control, and improved survival in this model vs. any other treatment group including the SBRT + αPD-1 and SBRT + CCR2/5i treatment groups (Fig. 3, D and E). The gene discussed is CCR2; the disease is neoplasm.